Free Trial
NASDAQ:PSTV

Plus Therapeutics Q1 2026 Earnings Results & Report

Plus Therapeutics logo
$0.95 +0.18 (+23.32%)
As of 11/13/2026

Plus Therapeutics missed analyst earnings expectations but beat on revenue in its Q1 2026 results, released May 15, 2026. The company reported EPS of -$1.05 versus the -$0.8480 consensus estimate, while revenue of $1.03 million topped the $974 thousand estimate by $54.00 thousand.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Plus Therapeutics EPS Results

Actual EPS
-$1.05
Consensus EPS
-$0.8480
Beat/Miss
Missed by -$0.2020
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Plus Therapeutics Revenue Results

Actual Revenue
$1.03 million
Expected Revenue
$974 thousand
Beat/Miss
Beat by +$54.00 thousand
YoY Revenue Growth
N/A

Plus Therapeutics Q1 2026 Earnings FAQ

Plus Therapeutics (NASDAQ:PSTV) reported earnings of -$1.05 per share for Q1 2026, missing the consensus estimate of -$0.8480. The report was announced on Friday, May 15, 2026.

Plus Therapeutics reported revenue of $1.03 million for Q1 2026, against a consensus estimate of $974 thousand.

Plus Therapeutics Earnings Headlines

Plus Therapeutics (NASDAQ:PSTV) Stock Falls 4.1% - What's Next?
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
See More Plus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email.

About Plus Therapeutics

Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage biotechnology company developing targeted treatments and diagnostic tools for cancers affecting the central nervous system. Its work includes radiopharmaceutical therapies designed to deliver radiation to tumors while limiting exposure to surrounding healthy tissue.

The company’s lead therapeutic program is Rhenium-186 NanoLiposome (RNL), an investigational treatment being studied for cancers including recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics also develops CNSide, a diagnostic platform intended to help detect and monitor cancer cells in cerebrospinal fluid.

Previously known as Cytori Therapeutics, the company adopted the Plus Therapeutics name in 2019. It is based in the United States and focuses its development programs on cancers of the brain and central nervous system.

View Plus Therapeutics Profile